Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years

Journal of Clinical Hypertension

Volumn 10, Issue 10, 2008, Pages 743-750

  Trachtman, Howard ^a   Hainer, James W ^b   Sugg, Jennifer ^b   Teng, Renli ^b   Sorof, Jonathan M ^b   Radcliffe, Jerilynn ^c   Vande Walle, Johan ^d   Szabo, Laszio ^e   Tulassay, Tivadar ^f   Turi, Sandor ^g   Marova, Eva ^h   Jurko, Alexander ⁱ   Horakova, Maria ^j   Achtel, Robert ^k   Barcia, John ^l   Batisky, Donald ^m   Brophy, Patrick ⁿ   Falkner, Bonita ^o   Flynn, Joseph ^p   Jenkins, Randall ^q   Kusnoor, Vijay ^r   Miller, Kenneth ^s   Paredes, Ana ^t   Restaino, Irene ^u   Sherbotie, Joseph ^v   Zilleruelo, Gaston ^w   Chiang, Myra ^x   Assadi, Farahnak ^y   Nagaraj, Shashi ^z   Sullivan, Janice ^aa   Aigbe, Michael ^ab   Portman, Ronald ^ac   Mak, Robert ^ad   Moritz, Michael ^ae   Williams, Robert ^af   Kupferman, Juan ^ag   Neufeld, Naomi ^ah   Stewart, Jimmy ^ai   Hanevold, Coral ^aj   Hazan, Lydia ^ak   Blummer, Jeffery ^al   Henshaw, Melissa ^am   Headley, David ^an   Primack, William ^ao   Feldenberg, L Richard ^ap   more..

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Miskolcc Mkh   (Hungary)

^f SEI Gyerm Klin   (Hungary)

^g SZTE Gyerm Klin   (Hungary)

^h Detska Kardiologicka ambulancia   (Slovakia)

ⁱ Detska Kardiologicke ambulancia   (Slovakia)

^j Detska Kardiologicke ambulancia ^*  (Slovakia)

^k Sutter North Medical Foundation   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

^m Pediatric Clinical Trials International   (United States)

ⁿ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^o THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^p ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^q Northwest Pediat Kidney Specialists   (United States)

^r Southeast Texas Clinical Research Center   (United States)

^s Nephrology and Hypertension Consultants   (United States)

^t MIAMI CHILDREN'S HOSPITAL   (United States)

^u CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w UNIVERSITY OF MIAMI   (United States)

^x Camcare Health Education and Research Institute   (United States)

^y RUSH UNIVERSITY MEDICAL CENTER   (United States)

^z WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^aa University of Louisville School of Medicine   (United States)

^ab Children's Nephrology Clinic   (United States)

^ac UNIVERSITY OF TEXAS   (United States)

^ad OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ae CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^af Georgia Clinical Professional Group   (United States)

^ag MAIMONIDES MEDICAL CENTER   (United States)

^ah Neufeld Medical Group   (United States)

^ai UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^aj MEDICAL COLLEGE OF GEORGIA   (United States)

^ak IMPACT Clinical Trials   (United States)

^al University   (United States)

^am MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^an Planters Clinic   (United States)

^ao Fallon Clinic   (United States)

^ap CHILDREN S HOSPITAL CENTRAL CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; PLACEBO; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; AREA UNDER THE CURVE; ARM FRACTURE; ARTICLE; CAUCASIAN; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NEGRO; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SORE THROAT; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; TETRAZOLES; TREATMENT OUTCOME;

EID: 58949094116     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00022.x     Document Type: Article

References (29)

1. Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475-482.
2. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. US Department of Health and Human Services. National Institute of Health; National Heart, Lung, and Blood Institute 2005:1-48.
3. Hanevold C, Waller J, Daniels S, et al. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: A collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113:328-333.
4. Daniels SR, Loggie JM, Khoury P, et al. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97:1907-1911.
5. Brady TM, Fivush B, Flynn JT, et al. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr. 2008;152:73-78.
6. Lande MB, Carson NL, Roy J, et al. Effects of childhood primary hypertension on carotid intima media thickness. A matched controlled study. Hypertension. 2006;48:40-44.
7. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr. 2006;149:746-754.
8. Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870-880.
9. Soffer B, Zhang Z, Miller K, et.al. A double-blind, placebo controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16:795-800.
10. Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18:183-190.
11. Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353-359.
12. Sorof JM, Cargo P, Graepel J, et.al. Beta-blocker/thiazide combination for treatment of hypertensive children: A randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17:345-350.
13. Blowey DL, Monica I, Scolnik D, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol. 1996;50:147-148.
14. Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007;22:695-701.
15. Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18:548-553.
16. Li JS, Berezny K, Kilaru R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44:289-293.
17. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999;33:1406-1413.
18. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effects of four AT-1 receptory blockers. Differences in potency and efficacy. Blood Press. 2002;11:293-301.
19. Meier CM, Simonetti GD, Ghiglia S, et al. Palatability of angiotensin II antagonists among nephropathic children. Br J Clin Pharmacol. 2006;63:628-631.
20. Chevalier RL. Developmental renal physiology of the low birth weight pre-term newborn. J Urol. 1996;156:714-719.
21. Lasaitiene D, Chen Y, Adams MA, et al. Further insights into the role of angiotensin II in kidney development. Clin Physiol Funct Imaging. 2006;26:197-204.
22. Schwartz GJ, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am. 1987;34:571-590.
23. Stenhoff H, Lagerstrom PO, Andersen C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J Chromatogr B. 1999;73:411-417.
24. Benjamin DK, Smith PB, Jadhav P, et al. Pediatric antihypertensive trial failures: Analysis of end points and dose range. Hypertension. 2008;51:834-840.
25. Batisky DL, Sorof JM, Sugg J, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16years of age: A clinical trial experience. J Pediatr. 2007;150:134-139.
26. Wells T, Blumer J, Litwin M, et al. Safety and effectiveness of valsartan (VAL) in hypertensive children ages 6 to 16years. J Clin Hypertens. 2007;9(Supp A):79-80.
27. Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan cilexetil in black patients with systemic hypertension: The ABC trial. Heart Dis. 2000;2:392-399.
28. Simonetti GD, von Vigier RO, Konrad M, et al. Candesartan cilexetil in children with hypertension or proteinuria: Preliminary data. Pediatr Nephrol. 2006;21(10):1480-1482.
29. Franks AM, O'Brien CE, Stowe CD, et al. Candesartan cilexetil effectively reduces blood pressure in hypertensive children. Ann Pharmacother. Pharmacotherapy. 2008; 42 (10): 1388-1395.